Revvity, Inc.
General ticker "RVTY" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $10.8B (TTM average)
Revvity, Inc. follows the US Stock Market performance with the rate: 56.4%.
Estimated limits based on current volatility of 1.6%: low 126.57$, high 130.57$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-07-17, amount 0.07$ (Y0.21%)
- Total employees count: 11000 (0.0%) as of 2025
- China accounted for 16.3% of revenue in the fiscal year ended 2024-12-29
- US accounted for 39.8% of revenue in the fiscal year ended 2024-12-29
- Top business risk factors: Economic downturns and volatility, Geopolitical risks, Market competition, Regulatory and compliance, Supply chain disruptions
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-28 to 2027-12-28
- 2025-12-28 to 2026-12-28 estimated range: [87.77$, 119.12$]
- 2026-12-28 to 2027-12-28 estimated range: [89.67$, 122.33$]
Financial Metrics affecting the RVTY estimates:
- Negative: with PPE of 19.1 at the end of fiscal year the price was very high
- Positive: 7.80 < Operating profit margin, % of 12.49
- Positive: 42.26 < Shareholder equity ratio, % of 59.58 <= 63.63
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 1.93
- Positive: 0.28 < Operating cash flow per share per price, % of 5.31
- Positive: Investing cash flow per share per price, % of -0.16 > -0.64
- Positive: Interest expense per share per price, % of 0.81 <= 3.34
- Negative: Industry earnings per price (median), % of -0.47 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term RVTY quotes
Relationship graph
Long-term RVTY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-29 | 2025-12-28 |
|---|---|---|---|
| Operating Revenue | $2,750.57MM | $2,755.03MM | $2,856.05MM |
| Operating Expenses | $2,450.01MM | $2,408.28MM | $2,499.42MM |
| Operating Income | $300.56MM | $346.74MM | $356.63MM |
| Non-Operating Income | $-117.59MM | $-30.61MM | $-88.36MM |
| Interest Expense | $117.59MM | $30.61MM | $88.36MM |
| R&D Expense | $216.58MM | $196.84MM | $215.84MM |
| Income(Loss) | $182.98MM | $316.13MM | $268.28MM |
| Taxes | $3.47MM | $33.05MM | $28.39MM |
| Other Income(Loss) | $513.59MM | $-12.69MM | $1.32MM |
| Net Income(Loss)* | $-118.38MM | $270.38MM | $241.20MM |
| Stockholders Equity | $7,872.74MM | $7,666.87MM | $7,250.36MM |
| Inventory | $428.06MM | $367.59MM | $379.50MM |
| Assets | $13,564.67MM | $12,392.48MM | $12,168.41MM |
| Operating Cash Flow | $91.27MM | $628.30MM | $582.93MM |
| Capital expenditure | $81.37MM | $86.65MM | $73.52MM |
| Investing Cash Flow | $1,313.52MM | $776.16MM | $-17.35MM |
| Financing Cash Flow | $-947.12MM | $-1,128.23MM | $-857.52MM |
| Earnings Per Share** | $-0.95 | $2.20 | $2.13 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.